Climb Bio, Inc.
CLYM
$6.97
-$0.16-2.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 37.57% | 53.25% | 108.19% | 138.35% | 55.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 151.39% | 149.46% | 240.66% | 179.52% | 25.79% |
| Operating Income | -151.39% | -149.46% | -240.66% | -179.52% | -25.79% |
| Income Before Tax | 19.01% | 26.58% | 27.16% | -540.10% | -110.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.01% | 26.58% | 27.16% | -540.10% | -110.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.01% | 26.58% | 27.16% | -540.10% | -110.42% |
| EBIT | -151.39% | -149.46% | -240.66% | -179.52% | -25.79% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 58.47% | 64.60% | 67.47% | -344.98% | -62.22% |
| Normalized Basic EPS | -135.11% | -60.53% | -45.91% | -24.30% | 46.45% |
| EPS Diluted | 58.47% | 64.60% | 67.47% | -344.98% | -62.22% |
| Normalized Diluted EPS | -135.11% | -60.53% | -45.91% | -24.30% | 46.45% |
| Average Basic Shares Outstanding | 42.52% | 75.55% | 136.95% | 110.44% | 75.78% |
| Average Diluted Shares Outstanding | 42.52% | 75.55% | 136.95% | 110.44% | 75.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |